Here are the S-1 registration statements from Vogenx Inc (VOGX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow VOGX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VOGX filings page.
Vogenx, Inc. (VOGX), a clinical-stage biopharma focused on metabolic diseases such as post-bariatric hypoglycemia (PBH) and gastroparesis, is pursuing an initial public offering of 6,250,000 shares of common stock at an expected price range of $11.00–$13.00 per share, with an application to list on the Nasdaq Capital Market under the symbol VOGX. The company is advancing its lead SGLT1 inhibitor, mizagliflozin, now in Phase 2b preparation for PBH and planning Phase 2 trials in gastroparesis and GIP-dependent Cushing’s Syndrome.
Assuming a $12.00 midpoint price, Vogenx estimates net IPO proceeds of about $67.8 million (or $78.2 million with full underwriter option), boosting pro forma cash to roughly $68.0 million and stockholders’ equity to about $67.1 million. Funds are earmarked primarily for continued development of mizagliflozin, other R&D, and general corporate purposes. Vogenx is an emerging growth company and smaller reporting company, with no revenue to date and net losses of $2.2 million in 2024, $1.4 million in 2025, and $0.5 million in the first quarter of 2026.